"Naloxone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.
| Descriptor ID |
D009270
|
| MeSH Number(s) |
D03.132.577.249.706 D03.605.497.750 D03.633.400.686.750 D04.615.723.795.706
|
| Concept/Terms |
MRZ-2593- MRZ-2593
- MRZ 2593
- MRZ2593
- MRZ 2593-Br
- MRZ 2593 Br
- MRZ 2593Br
|
Below are MeSH descriptors whose meaning is more general than "Naloxone".
Below are MeSH descriptors whose meaning is more specific than "Naloxone".
This graph shows the total number of publications written about "Naloxone" by people in this website by year, and whether "Naloxone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 4 | 4 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 3 | 4 |
| 2000 | 1 | 2 | 3 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Naloxone" by people in Profiles.
-
Tabatabai M, Cooper RL, Wilus DM, Edgerton RD, Ramesh A, MacMaster SA, Patel PN, Singh KP. The Effect of Naloxone Access Laws on Fatal Synthetic Opioid Overdose Fatality Rates. J Prim Care Community Health. 2023 Jan-Dec; 14:21501319221147246.
-
Livingston CJ, Berenji M, Titus TM, Caplan LS, Freeman RJ, Sherin KM, Mohammad A, Salisbury-Afshar EM. American College of Preventive Medicine: Addressing the Opioid Epidemic Through a Prevention Framework. Am J Prev Med. 2022 09; 63(3):454-465.
-
Santiago D, Rosario Y, Melin K, Duconge J, Roman L, Gonzalez A, Venkataramanan R. Brand-to-Generic Substitution of Buprenorphine/Naloxone Sublingual Film in Puerto Rico: A Case Study. P R Health Sci J. 2021 12; 40(4):192-194.
-
Saraiya P, Hutchins SS, Crump S, Morgan J, Wilkinson T, Walker CD, Taylor B. Availability of Naloxone in 2 Underserved Urban Communities in Georgia. J Public Health Manag Pract. 2021 May-Jun 01; 27(Suppl 3):S179-S185.
-
Uyei J, Fiellin DA, Buchelli M, Rodriguez-Santana R, Braithwaite RS. Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study. Lancet Public Health. 2017 03; 2(3):e133-e140.
-
Lutfy K, Parikh D, Lee DL, Liu Y, Ferrini MG, Hamid A, Friedman TC. Prohormone convertase 2 (PC2) null mice have increased mu opioid receptor levels accompanied by altered morphine-induced antinociception, tolerance and dependence. Neuroscience. 2016 08 04; 329:318-25.
-
Moniruzzaman M, Hossain MS, Bhattacharjee PS. Evaluation of antinociceptive activity of methanolic extract of leaves of Stephania japonica Linn. J Ethnopharmacol. 2016 Jun 20; 186:205-208.
-
Tseng A, Nguyen K, Hamid A, Garg M, Marquez P, Lutfy K. The role of endogenous beta-endorphin and enkephalins in ethanol reward. Neuropharmacology. 2013 Oct; 73:290-300.
-
Prenus RV, Luscar E, Zhu ZP, Badisa RB, Goodman CB. Regulation of mammalian MOR-1 gene expression after chronic treatment with morphine. Int J Mol Med. 2012 Dec; 30(6):1493-7.
-
Martinez CO, Do VH, Derrick BE. Endogenous opioid peptides contribute to associative LTP in the hippocampal CA3 region. Neurobiol Learn Mem. 2011 Sep; 96(2):207-17.